Allan Rettie

Allan Rettie is a Professor in the Department of Medicinal Chemistry at the University of Washington School of Pharmacy. He joined the faculty in 1987 and served as Department Chair from 2000-2014. His work focuses on drug metabolism, pharmacogenomics, and toxicology, particularly studying cytochrome P450 enzymes and their role in drug interactions and adverse reactions.

• PhD in Pharmaceutical Sciences, University of Newcastle-upon-Tyne, England
• BSc, Heriot-Watt University, Scotland
• Postdoctoral Fellow, University of Washington

Dr. Rettie's research centers on the biochemistry and pharmacogenetics of human P450 enzymes, with specific focus on the vitamin K cycle, CYP2C9 and warfarin metabolism, and CYP4 family enzymes. His laboratory investigates mechanisms of catalysis, substrate specificity, pharmacogenetic variability, and adverse drug reactions related to these monooxygenases. His work has significant implications for precision medicine and individualized drug therapy, particularly for anticoagulant drugs.

His recent publications demonstrate continued focus on P450 enzymes, warfarin pharmacokinetics, drug-gene interactions, and natural product-drug interactions (particularly kratom). His research combines genetic re-engineering, protein biochemistry, mass spectrometry, and synthetic chemistry to understand structure-function relationships in P450 enzymes and their impact on drug response and disease.

• North American Scientific Achievement Award from ISSX (2005)
• Fellow of the Japanese Society for the Study of Xenobiotics (2016)

Dr. Rettie has successfully held NIH research grants for over 25 years, demonstrating sustained funding success in his field. His laboratory has published over 190 peer-reviewed papers. Notably, he is not currently taking students. He has served on multiple editorial boards including Drug Metabolism and Disposition, Journal of Pharmacology and Therapeutics, and Chemical Research in Toxicology, and has participated in numerous NIH grant review panels. He has held leadership positions including Past Chair of the International Union of Basic and Applied Pharmacology's Section of Drug Metabolism and Transport.

His laboratory utilizes advanced techniques including genetic re-engineering of P450 proteins, mass spectrometry for analyte quantification, lipidomic analysis, and synthetic chemistry for developing novel substrates and inhibitors. Current projects include studying CYP4 enzymes as potential drug targets, investigating orphan P450s like CYP4V2 and CYP4Z1, and developing knockout mouse models to evaluate roles in chemical toxicity and disease.